Looks like a pennant flag on the weekly. Hopefully March newsletter will have something good.
Printable View
Looks like a pennant flag on the weekly. Hopefully March newsletter will have something good.
No it doesn't it looks like a Kandinsky.
Info from NZ Herald. Paywall. Cancer diagnostic firm Pacific Edge and Skellerup Holdings will soon be added to the FTSE Global Small Cap Index. Skellerup surged 35c or 8.33 per cent to $4.55, and Pacific Edge climbed 7c or 6.93 per cent to $1.08.
https://www.nzherald.co.nz/business/...X35WFTW4Z4LQ4/
Thanks for posting GWD, I did a little search and didn't come up with anything.
No problems TGB, I only discovered it reading the column apart from that I was sort of scratching my head for todays increase.
Hi 'Balance' and those in the know with PEB,
Any ideas why whenever there seems to be a little push up higher with the share price for PEB currently there seems to be a lot of resistance which then reverts the surge. Wouldn't those invested in PEB want to raise their sell orders at least into the 1.2-1.3 range to allow the share price to climb back up to where it was sitting for a while, and could comfortably retain at.
With continued growth and positive outlook for the company I don't see why some people seem to hinder the stock progressing moving forward. Or is it mainly just new retail traders just trying to make a bit of a quick buck, rather than looking at the bigger picture and letting the share price climb naturally higher. I don't see why there are so many sellers in the 1.1 range. If only they would just cancel there sell orders and allow the share price to push back up. Personally I feel these shares will soon be looked back on as a bargain at todays price.
Disclosure.
1- I am quite a large long term holder as I believe PEB are now on course to see some real growth with CX bladder, and believe it is a solid investment.
2- I am not soliciting a Reddit style push higher on the share price. I am just questioning why investors would be undercutting themselves for where the share price would otherwise be heading, if the ~850,000 sell orders for shares at 1.07 /1.1 were not sitting there restricting the market ever time it starts to push higher again. The chances that those sellers even read this is probably extremely unlikely anyway.
Thanks
I don't think it's just investors or traders moving the price here(up or down). I think there is a lot of bot trading going on and who knows how these algorithms work(maybe someone more experienced here might be able to see this clearly). Recently on PEB I noticed the trade volume seems to increase after the southeast asians markets open around 2pm NZ time onwards. In saying that I doubt the share price will move up to previous highs until we see something good maybe in the upcoming newsletter.
[QUOTE=Maxtrade;874093]
"With continued growth and positive outlook for the company I don't see why some people seem to hinder the stock progressing moving forward".
You might ask the same question of the 100 buyers sitting within 4 cents not prepared to advance their bids and in doing so hindering the stock progress upwards.
You might also consider that they are in fact hindering any progress downwards which after a long and agonizing plunge to around 7 cents and back to 1.26 is encouraging.
Two points to note :
1. PEB has been and is still an excellent trading stock for some of the players out there - so we will continue to see traders play with the stock for the 5% to 10% they can make. If they buy at $1.00, out they go at $1.05 to $1.10 - theirs is not a long term game and they also have to watch out for one another to see who gets in and out faster than the other!
The traders who missed out on the index-induced announcement surge on 22 Feb to $1.08 are lining up presumably today to get taken out.
Recall the NZX50 inclusion in October 2020 which saw the stock surged from 65c to 78c, then retracing down !0% back to 69c post index inclusion?
2. PEB is still very much an event driven stock - until such time as the cash starts pouring in from sales, this will continue to be the case.
https://www.odt.co.nz/business/globa...nation-dunedin
"For us going forward, we have to get some serious capital and start doing more of what we’ve done."
The business update newsletter due out in the next few weeks (as confirmed with investor relations) should be telling.
Wouldn't be surprised if there was a capital raise this year, assuming CMS doesn't reimburse for past tests. However it shouldn't be all that dilutive given the current share price.
“ In the future, it was likely another hub lab would be set up in Singapore for logistical reasons.”.
Was that an analysis from the reporter or DD’s confidence from increasing uptake in that region? I don’t remember this mentioned in previous meetings or it’s just inevitable if numbers are increasing.
Singapore is another area they have been working on. Natural to have this as a hub as not far from next large market China.
When David Darling is talking about " serious capital " I doubt he's referring to going back to existing shareholders via the NZX to raise funds. I think " serious capital " would more likely be a listing on an offshore exchange or partnering up with a larger existing market player. I think the days of raising 30 or 40 million locally are probably over.
Sounds about right since he is talking about global domination 😂 - “ We have global domination from Dunedin, that’s our plan and we love being here.”
342036.pdf (nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com)
Salt taking some profits off the table.
...... Mistake
https://www.nzx.com/announcements/368849
Like what she has to say in regards to positive outlook on future growths
This part also appeals "Glaxo Smith Kline". Nice timing by the company being International Woman Week. Good PR
My thoughts also, has that sentiment of women leading.
Sounds like she knows what's she doing anyway and has the experience and contacts to help pacific edge move further in the growth stages.
All the best to her.
And according to the amendment (http://nzx-prod-s7fsd7f98s.s3-websit...850/342040.pdf) they have actually reduced their holdings recently... I think....
As you were everyone...
Morning all.
Rookie question, is it common for independent directors to buy shares in a company?
If our new independent director buys shares in PEB would that be perceived as a great outlook for the future or is it normal behaviour, similar to the boards buying behaviour?
Thanks
Depends on how many they buy and at what prices.
There is tokenism and there is real commitment.
I must admit this is one I missed :
https://simplywall.st/stocks/nz/phar...nzsepeb-shares
is David building another deck?
Maybe his kid going to university overseas. Looks like the sell lot was under one of his family members name.
Could this have anything to do with the March newsletter and its potential positive or negative effects on the SP??
The last time DD "pulled this stunt" if I recall the SP was up in the 120 range and there was a rights issue going on at 40c.
Pretty obvious that DD hadnt expected the market reaction of taking off like a rocket after announcing a few providers signing up , all ably assisted by Balance giving 5.00 as a possible SP and something to look forward to.
I kid you not.
You are wrong of course.
$5.00? That was only the first stop towards $10.00 at least imo at that time.
That is until the failure to clarify & substantiate the 'several tens of thousands of tests' comment by the then Chairman Swann & the selling of shares by DD (twice) & the chairman after the very bullish comments, remember?
And the Huljichs & Masfens took the same opportunity to sell heaps of their shares as well on the back of the spike in the sp following the Chairman's extremely bullish comments?
One of the most disgraceful episodes in NZ's corporate history imo.
Dec 2013 when Swann made the comments & share sales by insiders took place in early 2014.
https://www.odt.co.nz/business/pacific-edge-business
“ ..... several tens of thousands of tests” in 2014 & US$100m revenues in 5 years.
Fast forward to 2020:
16,861 tests done in FY2020
Revenues NZ$4.4m
Looks like they were off by about 10 years haha! 100m might be possible by 2025 if new markets open up and US market is tracking according to plan without any major headwinds.
I noticed their cxbladder tests can now be bought online by anyone locally. Thought that was an interesting development. https://order.cxbladder.com/index.ph...&product_id=50
That's all in the past of course - what's important is how PEB is going to fare going forward with 2020 being the year of the reset imo.
2 things which will drive the sp in the next results = reimbursement of the US$40m tests done but not paid & how many tests done since the LCD was obtained.
Comfortable to hold until then.
PEB NZX Spotlight video this month
https://www.youtube.com/watch?v=NEwC4n8CWWc
Sorry Balance, could you remind me where this $40m figure is coming from for the potential CMS reimbursement? There are 22,000+ tests which they are negotiating reimbursement for, and the agreed price per test from 1 July 2020 is US$760 per test. I can't quite tie up the $40m figure that seems to be bouncing around.
https://businessdesk.co.nz/article/c...-administrator
Pacific Edge is chasing 22,000 outstanding invoices dating back to 2015 as it seeks up to US$40 million in backpay from US medical aid administrator Novitas.
https://businessdesk.co.nz/article/c...-administrator
Pacific Edge is chasing 22,000 outstanding invoices dating back to 2015 as it seeks up to US$40 million in backpay from US medical aid administrator Novitas.
"Hello is that Novias? its PEB here could you pay us $40miilion?
Novitas: "do we have to?"
PEB: "no"
Novitas: "Goodbye"
So the conclusion we can come to with all that is that any competitor looking to enter the field would be obliged to stump up some 20,000 odd tests free of charge to get recognised.Would be a big ask, that one.Might look at the NZ US exchange rate as an indicator as to the amounts but it does seem that 40mill is a bit high.
Isn't that article from back in August 2020? About time they reported on how that's going.
A more recent article here https://businessdesk.co.nz/index.php...y?bibblio=true with a more positive note.
Interesting - massive volume traded on Friday, 12 million shares, almost all at 5:00pm close
FYI still trying to find a COO
The newsletter should be the next update supposed to be in March but they are usually late going by the last two newsletter cycles. So maybe 1st or 2nd week of April.
https://www.pacificedgedx.com/investors/key-dates/
It's say tomorrow on the Reap site.
Not sure how to share screenshots.
If you download the app REAP.
It's got all the NZ companies and the latest information.
A nice cleaner version of the NZX announcement board, you can find it there.
You can also include only your companies of who you are concerned. So cut out the noise.
Gets reliable fast notifications of announcements without checking the NZX board.
Add the company and check events section
Sorry guys, not sure its an announcement maybe only notice of half year end.
Still a good app
Yes- Reap app is great. And free!
New Agreement https://www.nzx.com/announcements/370004
How is this not price sensitive?
Announcement made just in time to stop the SP dropping below the 100 day MA
Facey website lists 4 urologists on staff.
If we make a few assumptions, we can get an extremely rough ballpark figure.
1) Assume all four include cxbladder in their processes.
2) Assume each urologist refers a single patient for one of the cxbladder tests once per day. (Biggest assumption, I have no basis for this one, someone with knowledge please chip in..)
3) Assume Facey are paying the same CMS-agreed rate of US$760 per test.
4) Assume 48 clinic weeks a year, gotta let them rest sometime.
4 Urologists x 5 tests a week x 48 weeks x $760 = $729,600 USD potential contribution to revenue.
As above.. all assumptions. Final figure could be a 10% of this number, could be double, or something else entirely. Would dearly love to hear from someone experienced who could zero in on how many patients a Urologist may have cause to refer for testing in any given week.
Overall, I feel this is more a potential foot in the door to another large payer, and consider it an extremely good sign that they sought out PEB themselves after using the tests and finding them beneficial.
This is important but seems to be missed:
Facey Medical Group is a multi-specialty medical group with over 180 physicians providing care to more than 170,000 patients in the North & East regions of Los Angeles & Ventura Counties in California. This makes it similar in size to the Mid-Central District Health Board in New Zealand. Facey Medical Group is also one of six California physician groups affiliated with, or owned by Providence Health & Services, one of the largest health systems in the Western United States.
Also it is not just about urologists as some physicians will be involved as well. So a bit hard to put any kind of figure on it.
I’m heavily invested in both PEB and IKE and great to see them both making steady progress in USA. Both featuring on the leaderboard today. Onwards and upwards.
Very positive news. We have family members who are doctors/ urologists US based and apparently CX is starting to be heard of and abuzz. Integration is likely to follow more mainstream public health sectors as positive reviews flow. This is a good stepping stone, and the recognition here is wonderful for PEB. Great news. We will secure some more shares while the SP is still low at 1.02. This will seem like a bargain price within a short period of time. Looks like the analysts targets of 1.4 within the year is well on the cards :)
probably seen this before as it's from early Feb https://www.urologytimes.com/view/bladder-cancer-biomarker-test-accurately-adjudicates-atypical-cytology
Some good, positive publicity for CXBladder's effectiveness.
Full Year result 28th May. As for Investor Update - any day..
Any idea what "information" is "in public domain."?
https://www.odt.co.nz/business/pacific-edge-praised
Did they announce anything to the NZX yesterday ????
That article is dated 2014, so don’t think it’s that.
My guess is something was published in the states to their surprise that is material and they need to halt trading to catch up and comply.
I think it's good news. With new acting directors and facey medical now on board. A new team for growth its got to be something big, maybe another country or another organisation using Cx Bladder?
Pure speculation but I would rather remain positive
Usually when a company needs to halt trading in their shares due to something in the public domain (what ever that is) it isn't good news...
Yes but not always. Is there a correction possibly? Been no recent announcement apart from Facey medical
Perhaps the long awaited payout from CMS for services rendered or conversely confirmation its not coming.
Hope its the former.
Direction of sp in last few days can provide a clue but in this case, nothing conclusive - sp directionless on light volumes since indexing pushed sp up to $1.04 on 19 March.
Sounds to me like there's information being shared in the market which has been brought to PEB's attention for comment and it's material & significant enough to warrant a trading halt.
Could be very positive or very negative - not in-between, I would say! :scared:
https://www.nzx.com/announcements/370436
Sounds like very good news!
It's very good news.
This will make CX bladder more accessible and allow for more room to move through the medical world I would hope.
Bit of a worry they took a week to release the announcement .......
Fantastic news for PEB - onwards and upwards from here.
I was a bit worried the Trading Halt might have signified a T/O bid - until I read it. Much too soon for one of those for current shareholders but I wouldn't mind betting there will be a number of US companies with eyes on PEB over the next year or so.
Great news!
"Effective from 1 April 2021, Cxbladder is now being covered as a ‘medically necessary bladder tumor marker test’, under United Healthcare’s Molecular Pathology/Molecular Diagnostics/Genetic Testing (Medicare Advantage) - Medical Policy.
United Healthcare has over 50 million members with more than 5.7 million Medicare Advantage members. In 2019, UnitedHealth Group had a 14.1 percent share of the U.S. health insurance market, with direct premiums written amounting to approximately US$107 billion . The organisation partners with 6,500 hospitals and care facilities nationwide, and more than 1.3 million physicians and other providers."
Sharemarket likes it.